OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - VERTEX PHARMACEUTICALS OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - VERTEX PHARMACEUTICALS Share Price
Certificat
DE000SF7UWJ0
| Market Closed - Deutsche Boerse AG 20:45:43 11/06/2024 BST | ||
| 26.93 EUR | -0.66% |
|
| Current month | +10.87% | ||
| 1 month | +25.26% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 11/06/24 | 26.93 | -0.66% |
| 10/06/24 | 27.11 | +0.18% |
| 07/06/24 | 27.06 | +0.82% |
| 06/06/24 | 26.84 | +0.49% |
| 05/06/24 | 26.71 | +2.81% |
Delayed Quote Deutsche Boerse AG
Last update June 11, 2024 at 08:45 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SF7UWJ |
| ISIN | DE000SF7UWJ0 |
| Date issued | 18/08/2021 |
| Strike | 192.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.67 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 27.12 € |
|---|---|
| Lowest since issue | 1.63 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
481.5
USD
Average target price
463.4
USD
Spread / Average Target
-3.76%
- Stock Market
- Certificates
- Certificat